"aion" "loan"

Beyond Medical Technologies Ramps Up COVID Mask Manufacturing in Response to New South Africa COVID Variant

Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) ("Beyond Medical" or the "Company") is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. ("Micron Technologies").


New Variant of COVID-19

In response to the discovery of a new COVID-19 variant the federal government of Canada is implementing a travel ban on several south African countries including South Africa, Mozambique, Namibia, Zimbabwe, Botswana, Lesotho and Eswatini. In addition to Canada, the European Union, Israel, Japan, India, and Great Britain have all imposed travel bans on numerous South African countries. The restrictions have been implemented following the discovery of a new variant of COVID-19 in South Africa. South Africa's Minister of Health, Joe Phaahla, stated, "Initially, it looked like some cluster outbreaks, but from yesterday, the indication came from our scientists from the Network of Genomic Surveillance that they were observing a new variant."

The World Health Organization (WHO) declared the new variant identified in South Africa, named "Omicron", as a "variant of concern". The WHO deems new variants to be either a "variant of interest" or a "variant of concern", the latter being the more serious of the two. Further, a statement issued by the WHO on Friday stated "this variant has a large number of mutations, some of which are concerning" and that evidence gathered thus far indicates that the variant carried a higher risk of reinfection than other variants.

Manufacturing Three-Ply Medical Grade Face Masks at Full Capacity

Micron Technologies has been manufacturing and selling three-ply medical grade Level 3 face masks in Delta, B.C. since August 2020. Micron Technologies is manufacturing three-ply medical grade face masks pursuant its Medical Device Establishment License issued by Health Canada. Micron Technologies is also registered with the U.S. Food and Drug Administration.

Micron Technologies is currently operating two shifts per day to manufacture three-ply medical grade face masks. The three-ply medical grade face masks, which feature an adjustable nose clip designed to protect both front-line workers and consumers, offer three layers of protection and conform to the American Society for Testing and Materials' F2100 Level 3 standards.

Products for Retail

As previously announced, Micron Technologies' medical grade face masks are available to purchase through Walmart, Amazon and Shopify. Micron Technologies' black medical grade three-ply masks have achieved the status of '#1 best seller' on Amazon.

Institutional customers and those who are interested in obtaining a quote for large size orders are encouraged to contact Milan@micronti.com or sales@micronti.com. Customers can also make orders directly at https://micronti.com.

About Beyond Medical

Beyond Medical is an industrial/technology company with a manufacturing facility located in Delta, B.C. The Company, through its subsidiary Micron Technologies, manufactures medical grade face masks. For further information contact:

Kal Malhi, CEO
604-805-4602
kal@bullruncapital.ca

The Company is not making any express or implied claims that its products have the ability to eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus) at this time.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release. The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

FORWARD-LOOKING STATEMENTS:

This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Source


The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×